Quest Diagnostics (NYSE:DGX) is reiterated as a buy, aligning with market consensus, driven by anticipated sustained demand for diagnostic testing and its robust financial profile. The company exhibits strong cash flow and dividend growth, maintains superior margins, and shows progress in FDA approvals, all supported by an attractive balance sheet featuring an investment-grade BBB+ rating from Fitch and modest debt-to-equity. Potential risks include future Medicare rate adjustments and FDA regulatory actions.
Quest Diagnostics remains a buy, which is also what the consensus today said too. Quest can benefit from continued demand for specific diagnostic testing across a broad range of clinical areas. It has proven itself as a cash flow and dividend grower, achieving strong margins among peers and similar competitor Labcorp and making progress on FDA approvals. With an investment-grade BBB+ rating from Fitch and a modest D/E, the balance sheet profile is attractive. The risk of future Medicare rate decisions and FDA regulations or recalls has been discussed. The Stock: A Diagnostic Testing Leader With Some Bullish Signs As we wrap up another trading week, for this week's "Follow-up Friday," I'm taking another look at Quest Diagnostics (NYSE:DGX), which I called Albert Anthony is the pen name of a Croatian-American business author who is a media contributor on investor platform Seeking Alpha, where he has over +1K followers, & also writes for platforms like Investing dot com and is launching a book on Amazon in 2025 called Real Estate Investment Trusts (REITs): A Fundamental Analysis.The author comes from a non-traditional financial background having been an analyst in the IT sector for several Fortune 500 companies in the US, as well as the technical support team of financial firm Charles Schwab in 2021. This data-driven, process-oriented background has served him well in launching his own equities research firm, Albert Anthony & Company, which he manages 100% remotely. Having grown up in the New York City area to a 1st generation Croatian family in the US, he also called home the Austin Texas area, as well as the growing EU market of Croatia where he participated in dozens of business & innovation conferences, trade shows, and panel discussions. Albert Anthony completed degrees from Drew University, and is currently in the CMSA (Capital Markets & Securities Analyst) certification program at Vancouver-based Corporate Finance Institute(CFI). Besides appearing in financial media platforms, as a digital media enthusiast Albert Anthony also has been active in European casting agencies, having had extra roles in over 5 productions, as well as contributing or appearing in regional media channels in Croatia, and growing the Albert Anthony channel on YouTube where he will talk about REITs. For any business email please use his official mail address: contact@albertanthony.usPlease note: The author does not write about non-publicly traded companies, small cap stocks, or startup CEOs, so any such mail received and pitches from PR agencies will be deleted.Disclaimer: Albert Anthony and Albert Anthony & Co, as a US-based sole proprietorship registered as a trade name in Austin, Texas, are not registered financial advisors and do not provide personalized financial advisory to clients nor manage client funds but provide general markets commentary and research based on publicly-available data and our own analysis, and do not sell or market financial products and services, nor are compensated by any company for rating them. The author does not hold any material position in any stock he rates at the time of writing, unless otherwise disclosed. All investment is assumed to be at risk and readers are expected to do their due diligence beyond the scope of this author's commentary, agreeing to indemnify the author of any liability for potential investment losses. Show more Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. The investment thesis for Quest Diagnostics (DGX) is strongly bullish, supported by a consensus "buy" rating and a robust set of fundamental attributes. The company is positioned to benefit from continued, broad-based demand for diagnostic testing, which underpins its proven track record as a cash flow and dividend generator. Operationally, DGX demonstrates strong margins relative to competitors such as Labcorp and is making tangible progress on securing FDA approvals. The firm's financial health is a key strength, evidenced by an investment-grade BBB+ credit rating from Fitch and a modest debt-to-equity profile, which provides a solid foundation for growth. While the outlook is positive, two primary risks have been identified: the potential for adverse future Medicare rate decisions and the perpetual risk of new FDA regulations or product recalls, which could impact future profitability.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
